, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Premium Table of Contents
Karch’s Focus on Nursing Pharmacology, 10th Edition — Complete Original Practice Exam Bank
Section Coverage Chapters Questions Question Range
Introduction to Nursing
1 1–6 180 1–180
Pharmacology
Chemotherapeutic
2 7–14 240 181–420
Agents
Drugs Acting on the
3 15–18 120 421–540
Immune System
Drugs Acting on the
4 Central and Peripheral 19–28 300 541–840
Nervous Systems
Drugs Acting on the
5 Autonomic Nervous 29–33 150 841–990
System
Drugs Acting on the
6 34–38 150 991–1,140
Endocrine System
Drugs Acting on the
7 39–41 90 1,141–1,230
Reproductive System
Drugs Acting on the
8 42–49 240 1,231–1,470
Cardiovascular System
Drugs Acting on the
9 50–52 90 1,471–1,560
Renal System
Drugs Acting on the
10 53–55 90 1,561–1,650
Respiratory System
Drugs Acting on the
11 Gastrointestinal 56–60 150 1,651–1,800
System
TOTAL Complete Exam Bank 60 1,800 1–1,800
Complete Coverage
11 Major Sections • 60 Chapters • 1,800 Original Questions
Rationales • Why-Not Explanations • Clinical Pearls • Exam Strategies • Word-Stable Tables • Embedded Diagrams •
Graphs • Calculations
Independent educational practice bank for study alongside the textbook; not the publisher’s official test bank.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 2
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Section 1 — Introduction to Nursing Pharmacology
Chapter 1 — Introduction to Drugs
30 original questions • Questions 1–30
Question 1
During a refill review, a client reports that the new tablets have a different
color and manufacturer. The pharmacy confirms an FDA-approved generic
equivalent of the prescribed brand. Which explanation best addresses the
concern while preserving an appropriate safety check?
A. Use the new tablets at a reduced dose until comparable clinical
effectiveness is demonstrated.
B. Different appearance requires returning to the brand before the ingredient
list can be reviewed.
C. The active ingredient is equivalent, so excipient information is unnecessary
unless a new reaction occurs.
D. Verify the label and ingredient sensitivities; an approved equivalent may
differ in appearance.
Correct Answer: D
Rationale: An approved generic must meet requirements for equivalence to its
reference drug. Differences in appearance or permitted inactive ingredients do
not by themselves indicate reduced effectiveness. However, verification of the
actual product remains necessary. A history of sensitivity to a dye or another
excipient deserves specific review rather than blanket reassurance.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 3
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: A different appearance does not justify an unprescribed dose reduction.
B: Appearance alone does not establish that an approved equivalent is
unsuitable.
C: Equivalence does not make patient-specific excipient sensitivities
irrelevant.
Clinical Pearl: Verify the product and formulation before interpreting a
change in tablet appearance.
Exam Strategy: Choose reassurance that also preserves a relevant safety
assessment.
Source: clinical or regulatory background
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 4
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Question 2
Before the first participant receives an investigational drug, laboratory
evidence suggests potential benefit but also identifies toxicity at higher
exposures. What is the most defensible interpretation of these nonclinical
findings?
A. They allow the team to omit clinical monitoring for toxicities not observed
in the model.
B. They inform the exposure limits and safeguards for proposed initial human
testing.
C. They establish that the exposure effective in the model will also be
therapeutic in humans.
D. They require abandonment whenever any toxicity appears, even far above
proposed exposure.
Correct Answer: B
Rationale: Nonclinical research supports the assessment of risks before
human exposure. It informs starting-dose selection, monitoring, and other
safeguards rather than proving clinical effectiveness. Findings from
experimental systems cannot fully predict outcomes in people. Progression
therefore requires an appropriate regulatory and ethical framework for
human investigation.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 5
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: Unobserved toxicity remains possible when species, populations, and
exposure conditions change.
C: An experimental model cannot establish the therapeutic exposure or
response in humans.
D: The exposure associated with harm and the proposed clinical safeguards
must be evaluated; any toxicity does not automatically end development.
Clinical Pearl: Preclinical evidence informs the next investigation; it does
not complete the evidence chain.
Exam Strategy: Distinguish permission to investigate from approval to
market.
Source: clinical or regulatory background
Question 3
A protocol enrolls 48 volunteers in a first-in-human study, uses cautious dose
escalation, and repeatedly measures drug concentrations and adverse effects.
Which objective most strongly identifies this as a typical phase 1 study?
A. Confirming a benefit–risk profile through a large comparison with standard
care.
B. Selecting a useful dose range while obtaining preliminary efficacy data in
affected people.
C. Estimating uncommon harms across diverse community users after
marketing.
D. Characterizing initial human safety, tolerability, and pharmacokinetics.
Correct Answer: D
Rationale: Early human studies commonly concentrate on safety, tolerability,
dose exploration, and pharmacokinetics. Their size and design generally
cannot establish broad clinical effectiveness or rare-event risk. Some phase 1
studies enroll people with the target disease rather than healthy volunteers.
The study objective is a stronger clue than participant count alone.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 6
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: This is characteristic of later confirmatory development.
B: Preliminary efficacy and dose selection in affected populations are typical
phase 2 objectives.
C: This describes a postmarketing objective.
Clinical Pearl: Trial phase is identified by purpose as well as design and
population.
Exam Strategy: Match dose escalation and initial exposure with early safety
investigation.
Source: clinical or regulatory background
Question 4
Study summaries appear below. Which study most closely represents phase 2
development?
Study Participants and main purpose
W 36 volunteers; initial dose tolerance and drug concentrations
X 220 people with the target disorder; preliminary effectiveness and dose selection
Y 2,400 people with the target disorder; confirmatory comparison with standard treatment
Z Approved drug; additional long-term safety study in routine users
A. Study W
B. Study Y
C. Study Z
D. Study X
Correct Answer: D
Rationale: Study X evaluates an investigational treatment in people with the
condition it is intended to treat. Preliminary effectiveness and refinement of
dose selection are central phase 2 objectives. Safety assessment continues
during this phase. The numerical sample size supports the interpretation, but
the stated purpose is the decisive feature.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 7
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: Study W describes initial human safety investigation.
B: Study Y describes a larger confirmatory comparison.
C: Study Z describes a postapproval study.
Clinical Pearl: Safety evaluation continues throughout development rather
than ending after phase 1.
Exam Strategy: Read the objective before using enrollment size to identify
a phase.
Source: clinical or regulatory background
Question 5
A development team reports that an investigational drug improved symptoms
in a small uncontrolled study. It now proposes a larger randomized
comparison with standard treatment. A colleague argues that the observed
improvement already proves superiority. Which evaluation is strongest?
A. The comparator controls baseline differences, so concealed random
allocation adds no useful protection.
B. Randomization and a comparator help separate treatment effects from
imbalance and other influences.
C. The uncontrolled improvement establishes superiority, although
randomization may improve precision.
D. A larger uncontrolled cohort would address confounding as effectively as
random allocation.
Correct Answer: B
Rationale: Improvement in an uncontrolled group can reflect natural recovery,
concurrent care, or other influences. A randomized comparison strengthens
causal interpretation by reducing systematic baseline differences between
groups. It does not guarantee perfect balance or remove every source of bias.
Benefit and harm still require assessment using prespecified outcomes and
appropriate analysis.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 8
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: A comparator alone does not prevent systematic allocation differences
between groups.
C: Without a comparator, improvement may reflect natural history,
cointerventions, or other factors.
D: Increasing sample size does not by itself remove systematic confounding.
Clinical Pearl: A promising signal and a convincing comparative result are
different levels of evidence.
Exam Strategy: Identify what the proposed design adds to the earlier
evidence.
Source: clinical or regulatory background
Question 6
Two years after approval, a formal study is launched to investigate an
uncommon complication among people taking a medicine for longer periods
than those studied before approval. How should this activity be classified?
A. Routine individual case reporting rather than a formal postmarketing
study.
B. A phase 3 study because clinical safety questions cannot be studied after
approval.
C. A phase 4 study addressing a postmarketing safety question.
D. A phase 2 study because the complication was not a primary preapproval
outcome.
Correct Answer: C
Rationale: A formal study performed after approval can be classified as phase
4. Broader populations and longer exposure may reveal risks that earlier
studies could not reliably detect. Postmarketing surveillance also includes
activities other than phase 4 trials. A new safety finding warrants evaluation
but does not itself establish misconduct in the original review.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 9
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: The scenario describes an organized study, not only an individual
spontaneous report.
B: The study is explicitly conducted after approval to address longer-term use.
D: A new outcome does not automatically reclassify a postmarketing study as
phase 2.
Clinical Pearl: Approval begins routine access while safety evaluation
continues.
Exam Strategy: Separate formal postapproval studies from the wider
surveillance system.
Source: clinical or regulatory background
Diagram 1. Evidence before human exposure. Embedded Word-stable figure.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 10
Premium Table of Contents
Karch’s Focus on Nursing Pharmacology, 10th Edition — Complete Original Practice Exam Bank
Section Coverage Chapters Questions Question Range
Introduction to Nursing
1 1–6 180 1–180
Pharmacology
Chemotherapeutic
2 7–14 240 181–420
Agents
Drugs Acting on the
3 15–18 120 421–540
Immune System
Drugs Acting on the
4 Central and Peripheral 19–28 300 541–840
Nervous Systems
Drugs Acting on the
5 Autonomic Nervous 29–33 150 841–990
System
Drugs Acting on the
6 34–38 150 991–1,140
Endocrine System
Drugs Acting on the
7 39–41 90 1,141–1,230
Reproductive System
Drugs Acting on the
8 42–49 240 1,231–1,470
Cardiovascular System
Drugs Acting on the
9 50–52 90 1,471–1,560
Renal System
Drugs Acting on the
10 53–55 90 1,561–1,650
Respiratory System
Drugs Acting on the
11 Gastrointestinal 56–60 150 1,651–1,800
System
TOTAL Complete Exam Bank 60 1,800 1–1,800
Complete Coverage
11 Major Sections • 60 Chapters • 1,800 Original Questions
Rationales • Why-Not Explanations • Clinical Pearls • Exam Strategies • Word-Stable Tables • Embedded Diagrams •
Graphs • Calculations
Independent educational practice bank for study alongside the textbook; not the publisher’s official test bank.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 2
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Section 1 — Introduction to Nursing Pharmacology
Chapter 1 — Introduction to Drugs
30 original questions • Questions 1–30
Question 1
During a refill review, a client reports that the new tablets have a different
color and manufacturer. The pharmacy confirms an FDA-approved generic
equivalent of the prescribed brand. Which explanation best addresses the
concern while preserving an appropriate safety check?
A. Use the new tablets at a reduced dose until comparable clinical
effectiveness is demonstrated.
B. Different appearance requires returning to the brand before the ingredient
list can be reviewed.
C. The active ingredient is equivalent, so excipient information is unnecessary
unless a new reaction occurs.
D. Verify the label and ingredient sensitivities; an approved equivalent may
differ in appearance.
Correct Answer: D
Rationale: An approved generic must meet requirements for equivalence to its
reference drug. Differences in appearance or permitted inactive ingredients do
not by themselves indicate reduced effectiveness. However, verification of the
actual product remains necessary. A history of sensitivity to a dye or another
excipient deserves specific review rather than blanket reassurance.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 3
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: A different appearance does not justify an unprescribed dose reduction.
B: Appearance alone does not establish that an approved equivalent is
unsuitable.
C: Equivalence does not make patient-specific excipient sensitivities
irrelevant.
Clinical Pearl: Verify the product and formulation before interpreting a
change in tablet appearance.
Exam Strategy: Choose reassurance that also preserves a relevant safety
assessment.
Source: clinical or regulatory background
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 4
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Question 2
Before the first participant receives an investigational drug, laboratory
evidence suggests potential benefit but also identifies toxicity at higher
exposures. What is the most defensible interpretation of these nonclinical
findings?
A. They allow the team to omit clinical monitoring for toxicities not observed
in the model.
B. They inform the exposure limits and safeguards for proposed initial human
testing.
C. They establish that the exposure effective in the model will also be
therapeutic in humans.
D. They require abandonment whenever any toxicity appears, even far above
proposed exposure.
Correct Answer: B
Rationale: Nonclinical research supports the assessment of risks before
human exposure. It informs starting-dose selection, monitoring, and other
safeguards rather than proving clinical effectiveness. Findings from
experimental systems cannot fully predict outcomes in people. Progression
therefore requires an appropriate regulatory and ethical framework for
human investigation.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 5
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: Unobserved toxicity remains possible when species, populations, and
exposure conditions change.
C: An experimental model cannot establish the therapeutic exposure or
response in humans.
D: The exposure associated with harm and the proposed clinical safeguards
must be evaluated; any toxicity does not automatically end development.
Clinical Pearl: Preclinical evidence informs the next investigation; it does
not complete the evidence chain.
Exam Strategy: Distinguish permission to investigate from approval to
market.
Source: clinical or regulatory background
Question 3
A protocol enrolls 48 volunteers in a first-in-human study, uses cautious dose
escalation, and repeatedly measures drug concentrations and adverse effects.
Which objective most strongly identifies this as a typical phase 1 study?
A. Confirming a benefit–risk profile through a large comparison with standard
care.
B. Selecting a useful dose range while obtaining preliminary efficacy data in
affected people.
C. Estimating uncommon harms across diverse community users after
marketing.
D. Characterizing initial human safety, tolerability, and pharmacokinetics.
Correct Answer: D
Rationale: Early human studies commonly concentrate on safety, tolerability,
dose exploration, and pharmacokinetics. Their size and design generally
cannot establish broad clinical effectiveness or rare-event risk. Some phase 1
studies enroll people with the target disease rather than healthy volunteers.
The study objective is a stronger clue than participant count alone.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 6
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: This is characteristic of later confirmatory development.
B: Preliminary efficacy and dose selection in affected populations are typical
phase 2 objectives.
C: This describes a postmarketing objective.
Clinical Pearl: Trial phase is identified by purpose as well as design and
population.
Exam Strategy: Match dose escalation and initial exposure with early safety
investigation.
Source: clinical or regulatory background
Question 4
Study summaries appear below. Which study most closely represents phase 2
development?
Study Participants and main purpose
W 36 volunteers; initial dose tolerance and drug concentrations
X 220 people with the target disorder; preliminary effectiveness and dose selection
Y 2,400 people with the target disorder; confirmatory comparison with standard treatment
Z Approved drug; additional long-term safety study in routine users
A. Study W
B. Study Y
C. Study Z
D. Study X
Correct Answer: D
Rationale: Study X evaluates an investigational treatment in people with the
condition it is intended to treat. Preliminary effectiveness and refinement of
dose selection are central phase 2 objectives. Safety assessment continues
during this phase. The numerical sample size supports the interpretation, but
the stated purpose is the decisive feature.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 7
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: Study W describes initial human safety investigation.
B: Study Y describes a larger confirmatory comparison.
C: Study Z describes a postapproval study.
Clinical Pearl: Safety evaluation continues throughout development rather
than ending after phase 1.
Exam Strategy: Read the objective before using enrollment size to identify
a phase.
Source: clinical or regulatory background
Question 5
A development team reports that an investigational drug improved symptoms
in a small uncontrolled study. It now proposes a larger randomized
comparison with standard treatment. A colleague argues that the observed
improvement already proves superiority. Which evaluation is strongest?
A. The comparator controls baseline differences, so concealed random
allocation adds no useful protection.
B. Randomization and a comparator help separate treatment effects from
imbalance and other influences.
C. The uncontrolled improvement establishes superiority, although
randomization may improve precision.
D. A larger uncontrolled cohort would address confounding as effectively as
random allocation.
Correct Answer: B
Rationale: Improvement in an uncontrolled group can reflect natural recovery,
concurrent care, or other influences. A randomized comparison strengthens
causal interpretation by reducing systematic baseline differences between
groups. It does not guarantee perfect balance or remove every source of bias.
Benefit and harm still require assessment using prespecified outcomes and
appropriate analysis.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 8
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: A comparator alone does not prevent systematic allocation differences
between groups.
C: Without a comparator, improvement may reflect natural history,
cointerventions, or other factors.
D: Increasing sample size does not by itself remove systematic confounding.
Clinical Pearl: A promising signal and a convincing comparative result are
different levels of evidence.
Exam Strategy: Identify what the proposed design adds to the earlier
evidence.
Source: clinical or regulatory background
Question 6
Two years after approval, a formal study is launched to investigate an
uncommon complication among people taking a medicine for longer periods
than those studied before approval. How should this activity be classified?
A. Routine individual case reporting rather than a formal postmarketing
study.
B. A phase 3 study because clinical safety questions cannot be studied after
approval.
C. A phase 4 study addressing a postmarketing safety question.
D. A phase 2 study because the complication was not a primary preapproval
outcome.
Correct Answer: C
Rationale: A formal study performed after approval can be classified as phase
4. Broader populations and longer exposure may reveal risks that earlier
studies could not reliably detect. Postmarketing surveillance also includes
activities other than phase 4 trials. A new safety finding warrants evaluation
but does not itself establish misconduct in the original review.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 9
, NURSING PHARMACOLOGY | PREMIUM PRACTICE EXAM BANK
Why the other options are less appropriate:
A: The scenario describes an organized study, not only an individual
spontaneous report.
B: The study is explicitly conducted after approval to address longer-term use.
D: A new outcome does not automatically reclassify a postmarketing study as
phase 2.
Clinical Pearl: Approval begins routine access while safety evaluation
continues.
Exam Strategy: Separate formal postapproval studies from the wider
surveillance system.
Source: clinical or regulatory background
Diagram 1. Evidence before human exposure. Embedded Word-stable figure.
Karch’s Focus on Nursing Pharmacology, 10th Edition • Complete 1,800-Question Bank | 10
